Prevalence of Resistance to Clarithromycin and Its Clinical Impact on the Efficacy of Helicobacter pylori Eradication

References

• Bazzoli F, Zagari RM, Fossi S, Pozzato P, Alampi G, Simoni P, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol 1994;6:773–7.
   Web of Science ®Google Scholar
• Axon ATR, Moayyedi P. Eradication of Helicobacter pylori: omeprazole in combination with antibiotics. Scand J Gastroenterol 1996;31 Suppl 215:82–9.
   Web of Science ®Google Scholar
• Goddard A, Logan R. One-week low-dose triple therapy: new standards for Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 1995;7:1–3.
   PubMed Web of Science ®Google Scholar
• Lind T, Veldhyzen van Zanten SV, Unge P, Spiller R, Bayerdörffer E, O’Morain C, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH-I study. Helicobacter 1996;1: 138–44.
   PubMedGoogle Scholar
• Adamek RJ, Szymanski C, Pfaffenbach B. Pantoprazole versus omeprazole in one-week low-dose triple therapy for cure of H. pylori infection. Gastroenterology 1997;112:A 53.
   Google Scholar
• Ellenrieder V, Fensterer H, Waurick M, Adler G, Glasbrenner B. Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1998;12:613–8.
   Google Scholar
• Adamek RJ, Szymanski C, Pfaffenbach B. Pantoprazole versus omeprazole in one-week low-dose triple therapy for cure of H. pylori infection. Am J Gastroenterol 1997;92:1949–50.
   Google Scholar
• Megraud F. Antibiotic resistance in Helicobacter pylori infection. Br Med Bull 1998;54:207–16.
   PubMed Web of Science ®Google Scholar
• Tompkins DS, Perkin J, Smith C. Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter 1997;2:185–7.
   Google Scholar
• Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997;11 Suppl 1:43–53.
   PubMed Web of Science ®Google Scholar
• Glupczynski Y, Goutier S, Van den Borre C, Butzler JP, Burette A. Surveillance of Helicobacter pylori resistance to antimicrobial agents in Belgium from 1989 to 1994. Gut 1995;37 Suppl 1:A 56.
   Google Scholar
• Broutet N, Guillon F, Sauty E, Lethuaire D, Megraud F. Survey of the in vitro susceptibility of Helicobacter pylori to antibiotics in France: preliminary results. Gastroenterology 1998;A1137.
   Google Scholar
• Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin—influence on treatment outcome. Am J Gastroenterol 1998;93:386–9.
   PubMed Web of Science ®Google Scholar
• Tillenburg B, Siehoff S, Becker T, Peitz U, Börsch G, Labenz J. Helicobacter pylori: pratherapeutische Resistenzlage in Deutschland (Ruhrgebiet). Z Gastroenterol 1997;35: 165–9.
   PubMedGoogle Scholar
• Logan RP, Gummert PA, Schaufelberger HD, Greaves RR, Mendelson GM, Walker MM, et al. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994;35:323–6.
   PubMed Web of Science ®Google Scholar
• Lind T, Megraud F, Unge P, Bayerdorffer E, O’Morain C, Spiller R, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116: 248–53.
   Google Scholar
• Moayyedi P, Ragunathan PL, Mapstone N, Axon AT, Tompkins DS. Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol 1998;33: 160–3.
   PubMed Web of Science ®Google Scholar
• Megraud F, Occhialini A, Doermann HP. Resistance of Helicobacter pylori to macrolides and nitroimidazole compounds. The current situation. J Physiol Pharmacol 1997;48 Suppl 4:25–38.
   Google Scholar
• Malfertheiner P. Compliance, adverse events and antibiotic resistence in Helicobacter pylori treatment. Scand J Gastroenterol 1993;196:34–7.
   Google Scholar
• Ellenrieder V, Glasbrenner B, Stoffels C, Bode G, Adler G. Qualitative and semi-quantitative value of modified 13C-urea breath test for identification of Helicobacterer pylori infection. Eur J Gastroenterol Hepatol 1997;9: 1085–9.
   PubMedGoogle Scholar
• Glupczynski Y, Labbe M, Hansen W, Croekaert F, Youras-sowsky E. Evaluation of the E-test for quantitative antimicrobial susceptibility testing of Helicobacter pylori. J Clin Microbiol 1991;29:2072–5.
   Google Scholar
• Bazzoli F. Italian omeprazole triple therapy—a 1-week regimen. Scand J Gastroenterol 1996;31 Suppl 215:118.
   PubMedGoogle Scholar
• Pieramico O, Zanetti MV, Innnerhofer M, Malfertheiner P. Omeprazole based dual and triple therapy for the treatment of Helicobacter pylori infection in peptic ulcer disease: a randomized trial. Helicobacter 1997;2:97–107.
   Google Scholar
• Van der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996;1:6–19.
   PubMedGoogle Scholar
• Wurzer H, Rodrigo L, Stamler D, Archambault A, Rokkas T, Skandalis N, et al. Short-course therapy with amoxycillinclarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. Aliment Pharmacol Ther 1997;11: 943–52.
   PubMedGoogle Scholar
• Schwartz H, Krause R, Siepman N, Haber M, Weissfeld A, Kidd S, et al. Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report. Helicobacter 1996;1:251–5.
   PubMedGoogle Scholar
• Cayla R, Zerbib F, Talbi P, Megraud F, Lamouliatte H. Pre and post treatment clarithromycin resistance of Helicobacter pylori strains: a key factor of treatment failure. Gut 1995;37:A 217.
   Google Scholar
• Suzuki J, Mine T, Kobayasi I, Fujita T. Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H. pylori resistance to this therapy in Japan. Helicobacter 1998;3:59–63.
   PubMedGoogle Scholar
• O’Morain C, Dettmer A, Rambow A, von-Fritsch E, Fraser AG. Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. Helicobacter 1996;1: 130–7.
   PubMedGoogle Scholar
• Moayyedi P, Langworthy H, Shanahan K, Tompkins DS, Dixon MF, Chalmers DM, et al. Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori. Helicobacter 1996;1:71–4.
   PubMedGoogle Scholar
• Harford W, Lanza F, Arora A, Graham D, Haber M, Weissfeld A, et al. Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. Helicobacter 1996;1:243–50.
   PubMedGoogle Scholar
• Miehlke S, Manes GA, Lehn N, Hele C, Stolte M, Bayerdorffer E. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 1997;11:323–9.
   PubMed Web of Science ®Google Scholar
• Labenz J, Ruhl GH, Bertrams J, Borsch G. Effective treatment after failure of omeprazole plus amoxycillin to eradicate Helicobacter pylori infection in peptic ulcer disease. Aliment Pharmacol Ther 1994;8:323–7.
   PubMedGoogle Scholar
• Bayerdörffer E, Miehlke S, Manes GA, Sommer A, Hochter W, Weingart J, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995;108: 1412–7.
   PubMed Web of Science ®Google Scholar